Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

Analyst Ratings

9 Analysts Have This to Say About Mohawk Industries

By Benzinga Insights

August 18, 3:26 PM

Mohawk Industries (NYSE:MHK) has observed the following analyst ratings within the last quarter:

MHK

AREX Capital Expresses Disappointment In Enhabit’s Strategic Review Conclusion; Believes Enhabit’s Shares Do Not Reflect Its Intrinsic Value Or Strategic Potential

By Benzinga Newsdesk

May 9, 9:40 AM

Believes Enhabit's Shares Do Not Reflect its Intrinsic Value or Strategic Potential Has Nominated Seven Highly Qualified Independent DirectorsBelieves AREX Slate Would Provide Board With Sorely Needed Home Health

EHAB

Analyst Ratings

Analyst Ratings for World Wrestling Enter

By Benzinga Insights

February 3, 4:00 PM

Over the past 3 months, 4 analysts have published their opinion on World Wrestling Enter (NYSE:WWE) stock. These…

WWE

News

Elon Musk Says Reports Of Him Meeting With Top U.S. Officials On EVs Is ‘True’

By Benzinga Newsdesk

January 27, 3:11 PM

https://twitter.com/elonmusk/status/1619049025357090816?s=20&t=gVewMYnmfvz44PG55nvV0A

Chardan Capital Downgrades Vascular Biogenics to Neutral

Related Posts

9 Analysts Have This to Say About Mohawk Industries

AREX Capital Expresses Disappointment In Enhabit’s Strategic Review Conclusion; Believes Enhabit’s Shares Do Not Reflect Its Intrinsic Value Or Strategic Potential

Analyst Ratings for World Wrestling Enter

Elon Musk Says Reports Of Him Meeting With Top U.S. Officials On EVs Is ‘True’